LGND Ligand Pharmaceuticals


From Benzinga Pro
Ligand And GSK Expand Global Collaboration And License Agreement; Ligand To Receive An Upfront Payment Of $10M And Is Eligible For Development And Regulatory Milestones Up To $67.5M
21 Dec 21
News, Contracts, Global
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK). The expansion will leverage
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
10 Nov 21
Biotech, Earnings, Long Ideas, News, Guidance, Health Care, Movers, Trading Ideas, General
Ligand Pharmaceuticals Q3 EPS $1.58 Beats $1.04 Estimate, Sales $64.83M Beat $55.65M Estimate
9 Nov 21
Earnings, News
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.04 by 51.92 percent. This is a 51.92 percent increase over earnings of $1.04 per share
Recap: Ligand Pharmaceuticals Q3 Earnings
9 Nov 21
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
9 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
9 Nov 21
Earnings, M&A, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.

Press releases

From Benzinga Pro
Ligand's Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
22 Dec 21
Press Releases
Sugemalimab was discovered using the OmniAb platform Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616) has received approval from China's National
Ligand and GSK Expand Global Collaboration and License Agreement
21 Dec 21
Press Releases
Ligand to receive an upfront payment of $10 million Further leverages the Icagen ion-channel discovery technology to target neurological diseases Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today the
Genedata Biologics Selected as Global Antibody Discovery Workflow Platform for Ligand Pharmaceuticals
14 Dec 21
Genedata Biologics integrates, automates, and streamlines Ligand Pharmaceuticals' OmniAb in vivo antibody discovery platform BASEL, Switzerland (PRWEB) December 14, 2021 Genedata, the leading provider of enterprise
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II
15 Nov 21
News, Financing, Press Releases
Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutationsInitial data from both
Ligand Reports Third Quarter 2021 Financial Results
9 Nov 21
Press Releases
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2021 and provided an operating
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
9 Nov 21
Press Releases
Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb's Drug Discovery Platform Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand